Expert Interview
A Second Look: Discussing the potential of Neurocrine Bio's recently FDA approved INGREZZA (valbenazine) for the treatment of Chorea associated with Huntington's Disease
Ticker(s): NBIXInstitution: University of Louisville
- Professor of Neurology, Medical Geneticist, Endowed Chair of Parkinson’s Disease Research, & Director, Movement Disorders Program at University of Louisville.
- Manages 90 patients with Huntington's disease and 35 patients with Friedreich’s Ataxia.
- Research interests are focused on understanding the underlying genetic basis of hereditary spastic paraplegia and essential tremor; clinical interests include surgical therapies for Parkinson's disease, essential tremor and dystonia, and botulinum toxin procedures for dystonia and spasticity.
How many patients with Huntington's disease do you currently treat?
Added By: chanell_adminAre you familiar with the results from the KINECT Phase 3 study which the FDA based the approval of INGREZZA from
Added By: chanell_adminWhat other movement disorders do you think the drug may have possibilities to treat?
Added By: chanell_adminWhat do you see as the share of the prescriptions you expect Ingrezza to have in different markets by 2030?
Added By: chanell_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
